HPE Growth

Public records do not identify the firm's current investment committee or named partners with specificity. HPE Growth's senior team has historically included professionals with prior experience at European private equity and growth platforms, but updated leadership structures have not been confirmed through primary sources. An allocator would verify the current decision-making matrix directly with the firm's investor relations team.

HPE Growth concentrates on expansion and late-stage growth equity in European technology companies. The firm enters after institutional venture backing has validated the product — typically at companies with €10 million to €50 million in recurring revenue that need scale capital rather than seed or Series A risk. This places HPE Growth firmly in the growth-equity corridor, with a bias toward profitability or near-breakeven operations.

The firm leverages its Amsterdam base in one of Europe's densest institutional investment hubs, combined with sector specialization in enterprise software, fintech, and digital health. HPE Growth's sourcing model relies on network-driven origination within the DACH region, Nordics, Benelux, and selectively the UK and Southern Europe. The firm's concentrated portfolio approach means it competes on hands-on board partnership rather than auction-process speed.

HPE Growth operates as a direct growth-equity investor, making minority and control equity investments in individual companies rather than participating as a fund-of-funds or limited partner in other managers' vehicles. The firm's own capital is raised through a closed-end institutional fund structure, and its deployment activity consists of direct platform investments with reserved follow-on capital.

HPE Growth has not publicly listed excluded sectors. However, its observed concentration in enterprise software, fintech, and digital health suggests the firm avoids deep-tech hardware, biopharma, and industrial manufacturing where its team's domain expertise and the European growth-equity thesis would not naturally extend. Allocators should confirm the current investment policy statement directly with the firm.